Long-term Outcome After Resection for Chronic Pancreatitis in 224 Patients

Department of Surgery, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Journal of Gastrointestinal Surgery (Impact Factor: 2.8). 09/2007; 11(8):949-59; discussion 959-60. DOI: 10.1007/s11605-007-0155-6
Source: PubMed


Organ complications like biliary or duodenal stenosis as well as intractable pain are current indications for surgery in patients with chronic pancreatitis (CP). We present here our experience with pancreatic resection for CP and focus on the long-term outcome after surgery regarding pain, exocrine/endocrine pancreatic function, and the control of organ complications in 224 patients with a median postoperative follow-up period of 56 months.
During 11 years 272 pancreatic resections were performed in our institution for CP. Perioperative mortality was 1%. Follow-up data using at least standardized questionnaires were available in 224 patients. The types of resection in these 224 patients were Whipple (9%), pylorus-preserving pancreato-duodenectomy (PD) (PPPD; 40%), duodenum-preserving pancreatic head resection (DPPHR; 41%, 50 Frey, 42 Beger), distal (9%) and two central pancreatic resections. Eighty-six of the patients were part of a randomized study comparing PPPD and DPPHR. The perioperative and follow-up (f/up) data were prospectively documented. Exocrine insufficiency was regarded as the presence of steatorrhea and/or the need for oral enzyme supplementation. Multivariate analysis was performed using binary logistic regression.
Perioperative surgical morbidity was 28% and did not differ between the types of resection. At last f/up 87% of the patients were pain-free (60%) or had pain less frequently than once per week (27%). Thirteen percent had frequent pain, at least once per week (no difference between the operative procedures). A concomitant exocrine insufficiency and former postoperative surgical complications were the strongest independent risk factors for pain and frequent pain at follow-up. At the last f/up 65% had exocrine insufficiency, half of them developed it during the postoperative course. The presence of regional or generalized portal hypertension, a low preoperative body mass index, and a longer preoperative duration of CP were independent risk factors for exocrine insufficiency. Thirty-seven percent of the patients without preoperative diabetes developed de novo diabetes during f/up (no risk factor identified). Both, exocrine and endocrine insufficiencies were independent of the type of surgery. Median weight gain was 2 kg and higher in patients with preoperative malnutrition and in patients without abdominal pain. After PPPD, 8% of the patients had peptic jejunal ulcers, whereas 4% presented with biliary complications after DPPHR. Late mortality was analyzed in 233 patients. Survival rates after pancreatic resection for CP were 86% after 5 years and 65% after 10 years.
Pancreatic resection leads to adequate pain control in the majority of patients with CP. Long-term outcome does not depend on the type of surgical procedure but is in part influenced by severe preoperative CP and by postoperative surgical complications (regarding pain). A few patients develop procedure-related late complications. Late mortality is high, probably because of the high comorbidity (alcohol, smoking) in many of these patients.

Download full-text


Available from: Tobias Keck,
  • Source
    • "After pancreatic surgery, the exocrine function is determined by the underlying pancreatic disease and the chosen surgical procedure (depending on the extent of the resection and the restoration of gastrointestinal tract continuity).3,4 Postoperatively, exocrine insufficiency is observed in 65 to 80 % of the patients with chronic pancreatitis.5,6 In patients with pancreatic cancer, exocrine insufficiency is found in 68 to 92 % before surgery and in 80 % after surgery.7 "
    [Show abstract] [Hide abstract]
    ABSTRACT: After pancreatic surgery, up to 80 % of patients will develop exocrine insufficiency. For enzyme supplementation to be effective, prescribing an adequate dose of pancreatic enzymes is mandatory but challenging because the required dose varies. Data on the practice of enzyme replacement therapy after surgery are lacking, and therefore, we conducted this analysis. An anonymous survey was distributed to members of the Dutch and German patient associations for pancreatic disorders. The target population consisted of patients with chronic pancreatitis or pancreatic cancer who had undergone pancreatic surgery and were using enzymes to treat exocrine insufficiency. Results were compared to a similar group of non-operated patients. Ninety-one cases were analyzed (84 % underwent a resection procedure). The median daily enzyme dose was 6, and 25 % took three or less capsules. Despite treatment, 68 % of patients reported steatorrhea-related symptoms, 48 % adhered to a non-indicated dietary fat restriction, and only 33 % had visited a dietician. The outcome was equally poor for the 91 non-operated patients. Most patients suffering from exocrine insufficiency after pancreatic surgery are undertreated. To improve efficacy, physicians should be more focused on treating exocrine insufficiency and educate patients to adjust the dose according to symptoms and their diet.
    Journal of Gastrointestinal Surgery 06/2012; 16(8):1487-92. DOI:10.1007/s11605-012-1927-1 · 2.80 Impact Factor
  • Source
    • "Chronic narcotic use, pancreaticoduodenectomy in small ductal system, mutiple abdominal surgeries before pancreatic intervention were associated with poor outcome [23]. In a recent report, preoperative exocrine insufficiency and postoperative surgical complications were found to be strongest predictors of poor pain outcome [26]. Frey and Amikura [23] advocate local resection of head for chronic pancreatitis with head mass irrespective of ductal diameter. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Debilitating abdominal pain remains the most common presentation of chronic pancreatitis and the treatment remains challenging. This prospective study analyzed the outcome of Frey's procedure in patients with inflammatory head mass. For the period between 2002 and 2007, 77 patients with chronic pancreatitis underwent Frey procedure for intractable abdominal pain. The mean follow-up was 14 months. For the purpose of analysis of the outcome, patients were grouped as poor pain control (19%) and good pain control groups (81%) based on the pain scores during follow-up. There was no 30-day mortality. The logistic regression analysis showed that decreased volume percentage (48%) of head mass resected (p=0.003) and small diameter of the pancreatic duct (p=0.05) were associated with poor pain outcome. Subgroup analysis revealed that patients with small duct disease were associated with increased operative time (p=0.001), poor pain scores (p=0.001), and increased weight loss (p=0.003) during follow-up. Frey procedure can be performed with zero mortality and low morbidity in a high-volume center. It provides good pain relief in majority of the patients. Volume of the head mass cored affects pain outcome. Correlation between poor results in terms of pain relief and weight loss following Frey's procedure, and small duct disease supports the view that duct diameter is an important predictor of pain relief.
    HPB 02/2008; 10(6):477-82. DOI:10.1080/13651820802392338 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: There are various surgical options for the treatment of pain associated with chronic pancreatitis. The modified Puestow lateral pancreaticojejunostomy has been proven to be effective in ameliorating symptoms and expediting return to normal lifestyle while maintaining a low rate of morbidity and mortality. However, the debate regarding which surgical treatment provides the best outcomes is controversial. OBJECTIVES: The aims of this manuscript are to identify the patient population for which the Puestow benefits the most and discuss the pertinent technical aspects of the surgical procedure.
    Journal of Gastrointestinal Surgery 08/2008; 13(5):1004-8. DOI:10.1007/s11605-008-0590-z · 2.80 Impact Factor
Show more